ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['lcsm,(-blcsm)', 'durva', 'aegean', 'cm816']
#cm816 3yr update was recently presented at #elcc23 (os: 0.67 and efs 57% at 3yrs/65% at 2yrs) and today, #aegean data was presented at #aacr23. how much is adjuvant durva adding here? unfortunately, we are left with cross trial comparisons given study design. #lcsm 
Practice changing 🗣 for community oncologists: w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own. COI: https://t.co/cJOjp0RvQE